ColorfulBio Secures RMB 150 Million Series B Financing to Advance Life Science Tools and In Vitro Diagnostics

Recently,Lychix (Suzhou) Biotechnology Co., Ltd. (hereinafter referred to as “Lychix” or the “Company”) announced the completion of its RMB 150 million Series B financing round,Jointly invested by Legend Capital, Honghui Capital, and SDIC Investment Promotion, with existing shareholder IDG Capital continuing to increase its investment. Following this round of financing, the company will further ramp up R&D investment, strengthen its talent team, enhance production capacity, and advance the commercialization of key products.

Life science tools constitute a critical segment of the life sciences industry. Whether in early-stage basic scientific research, upstream support for new drug development and manufacturing, or IVD diagnostic raw materials and high-end equipment, life science tools serve as core value drivers that underpin application innovation within the life sciences sector, acting as the source and foundation of innovation. With the rapid technological advancements in life sciences worldwide and the rise of China’s life sciences industry, Chinese life sciences enterprises are ushering in unprecedented historical opportunities.

Various life activities (such as cell motility, DNA replication and segregation, and ligand-receptor binding) are driven by forces at the molecular scale. Research into the micromechanics of single cells or individual biomolecules can enhance our understanding of life. Among various force-generation methods, forces produced by a single physical field often carry significant limitations. In contrast, micromechanical systems based on multiphysics coupling can not only improve the resolution of life science research but also enhance parallel manipulation capabilities, thereby enabling automation and industrial intelligence in microscopic biological systems.

Lychix, founded in 2018, is a company dedicated to providing advanced research tools for the life sciences. It aims to develop high-efficiency products to extract massive amounts of high-resolution life science data, primarily serving downstream industries such as life science research, biopharmaceutical R&D, and clinical diagnostics. Currently, leveraging its core technology platform, μ-MPF (Micro-scaled Multi-Physics Coupled Force), the company has established multiple application platforms, includingUltra-High Sensitivity Biomolecular Detection Platform, suitable for multi-parameter combined testingMultiplexed Magnetic-Fluorescent Encoding Microsphere Platformand applied to single-cell multi-omicsHigh-Throughput Single-Cell Parallel Manipulation Platform。

For this round of financing,Dr. Cheng Peng, Founder and CEO of LychixHe stated, “We are deeply grateful to top-tier life sciences investment firms for their support of the company. Lychix will remain dedicated to providing advanced research tools for the life sciences industry, facilitating the iterative advancement of life science technologies and the transformation of biopharmaceutical R&D paradigms. We look forward to engaging in extensive collaborations with leading domestic enterprises, enabling Lychix’s life science research tools to serve Chinese biopharmaceutical companies as soon as possible.”

Zhou Quan, Managing Director at Legend Capital“Advancements in tools are driving life science research toward the microscale, continuously opening up new application areas. Lychix boasts a rare, multidisciplinary team with strong collaborative efficiency and has built a high-barrier platform for micro-scale analytical tools. We are honored to partner with the company and look forward to supporting and witnessing its contributions to life science R&D and applications in China and around the world.”

Honghui Capital TeamLychix stated: “Lychix is dedicated to the continuous research and development of core technologies and their applications. Supported by the R&D strength and industrialization capabilities of the Lychix team, we look forward to delivering superior solutions to advance life science research and the development of the in vitro diagnostics industry.”

SDIC Investment Promotion Life Sciences Team“Lychix boasts a multidisciplinary R&D team with extensive experience, leveraging its independently developed innovative platforms to focus on the development of next-generation life science tools and diagnostic technologies. As the lead investor in this funding round, SDIC Capital Management highly recognizes the exceptional R&D capabilities and innovative spirit demonstrated by the Lychix team. We look forward to witnessing how the company’s digital biotechnology products continue to drive advancements in clinical and biomedical applications.”

Legend Capital was established in April 2001 as a fund management company under Legend Holdings, specializing in early-stage venture capital and growth-stage private equity investments. Over the past two decades, Legend Capital has adhered to international standards, creating best practices in fund operations and management.

Legend Capital drives corporate innovation and growth through its proactive value-added service system, generating strong investment returns across multiple sectors while advancing China’s industrial progress and social development.

Legend Capital envisions becoming an investment firm with global influence, upholds the core value of “Prosperity with Integrity,” and actively fulfills its social responsibilities.

Hillhouse Capital (HLC) is an asset management firm dedicated to driving technological innovation, leveraging deep industry insights as its core competency to empower key sectors such as biopharmaceuticals and consumer livelihood, thereby creating long-term value. HLC manages dual-currency funds in RMB and USD, with offices established in Shanghai, Beijing, and Shenzhen. To date, HLC has invested in over 90 high-quality enterprises, more than 20 of which are listed on the Shanghai Stock Exchange, Shenzhen Stock Exchange, Hong Kong Stock Exchange, and Nasdaq. Its investment portfolio includes WuXi Biologics, Mindray Medical, WuXi AppTec, SMORE International, Pharmaron, Tigermed, Yuwell Medical, Sansure Biotech, Kintor Pharmaceutical, BrightGene, Nayuki, Baiyang Pharma, Genesis MedTech, Kemei Diagnostics, Chaoju Eye Care, and Kaiyin Technology.

SDIC Investment Promotion focuses on investments in the advanced manufacturing industry, emphasizing technological innovation and the value of outstanding entrepreneurs and teams. It prioritizes investments in fields such as intelligent manufacturing, new energy intelligent vehicles, life sciences, and information and communications technology (ICT), committing to promoting the green, digital, and service-oriented development of the manufacturing sector. The team manages a cumulative asset scale exceeding RMB 100 billion, with investors including financial institutions, the National Social Security Fund, and both state-owned and private capital.

IDG Capital is a globally leading private equity investment firm. With nearly three decades of development, the firm has accumulated over RMB 150 billion in assets under management. IDG Capital focuses on leading enterprises in sectors such as the internet, new consumer goods and services, culture and entertainment, healthcare, advanced manufacturing, and clean energy. Its investment scope covers all stages, including early-stage, growth-stage, mature-stage, and mergers and acquisitions, with investment sizes ranging from millions to hundreds of millions of US dollars.